Jump to Navigation
Banner

Overview

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to address HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians.

 

Recent News
Jun 14, 2017

Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that Company Chairman and CEO, Jim Joyce will present...

Jun 6, 2017

Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced that James Joyce, CEO, will be presenting an overview...

View all News Releases

Events
Tuesday, June 6, 2017
11:30am PDT
Monday, April 3, 2017

Episode 17-13 Health Tec, the NFL, Major League Baseball and Neuroscience http://www.technation.com/

View All Events


print email

Back to Top


Site 'Subpage' Navigation:

Investor Relations

NASDAQAEMD
Investor Contact

Aethlon Medical, Inc.
858-459-7800

Back to Top